BclXL (Bcl2l1) gene therapy lessens retinal ganglion cell soma loss but not axonal degeneration after acute axonal injury

BclX_L (Bcl2l1) gene therapy lessens retinal ganglion cell soma loss but not axonal degeneration after acute axonal injury

Cell Death Discov. 2022 Jul 22;8(1):331. doi: 10.1038/s41420-022-01111-4.

Olivia J Marola^{1

2

3}, Sarah E R Yablonski^{1

3

4}, Peter G Shrager⁴, Robert W Nickells⁵, Richard T Libby^{6

7

8}

¹ Department of Ophthalmology, Flaum Eye Institute, University of Rochester Medical Center, Rochester, NY, USA.
² Cell Biology of Disease Graduate Program, University of Rochester Medical Center, Rochester, NY, USA.
³ The Center for Visual Sciences, University of Rochester, Rochester, NY, USA.
⁴ Department of Neuroscience, University of Rochester, Rochester, NY, USA.
⁵ Department of Ophthalmology and Visual Sciences, University of Wisconsin-Madison, Madison, WI, USA.
⁶ Department of Ophthalmology, Flaum Eye Institute, University of Rochester Medical Center, Rochester, NY, USA. richard_libby@urmc.rochester.edu.
⁷ The Center for Visual Sciences, University of Rochester, Rochester, NY, USA. richard_libby@urmc.rochester.edu.
⁸ Department of Biomedical Genetics, University of Rochester Medical Center, Rochester, NY, USA. richard_libby@urmc.rochester.edu.

No abstract available